SuperB Trial: SUrgical Versus PERcutaneous Bypass

Inclusion Criteria: * Age over 18 years * Informed consent * Novo stenosis, restenosis \>50% or occlusion of the native SFA, all \> 10cm in length * Patent popliteal artery at the upper margin of the patella to the trifurcation * Diameter native SFA and popliteal artery are 5.0-7.5 mm * Indication for surgical bypass * Distal run-off at least one crural artery without significant stenosis * Ankle-brachial index (ABI) at rest \< 0.8 in the study limb prior to procedure Exclusion Criteria: * Patient unsuitable for administration of contrast agent * Pregnancy * Dementia or altered mental status that would prohibit giving conscious informed consent * Need for adjunctive major surgical or vascular procedures within one month * Untreated flow-limiting aortoiliac occlusive disease * Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment * Femoral or popliteal aneurysm of target vessel * Non-arthrotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis) * Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancies, dementia etc.) or other medical condition that would preclude compliance with study protocol * Major distal amputation (above the transmetatarsal) in the study limb * Any previously known coagulation disorder, including hypercoagulability * Contraindication to anticoagulation or antiplatelet therapy * Known allergies to stent/stent-graft components * History of prior life-threatening reaction to contrast agent * Patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II * Planned surgical procedure or major amputation to occur after enrollment of the patient